-
Building Better Antibodies and Curbing Autoimmune Diseases
19 Apr 2024 17:31 GMT
… developing more broadly protective vaccines and antibody-based biologic treatments. … findings suggest new strategies for treating autoimmune diseases.
Want more breaking news? … pediatrics — further investigated how autoimmune disease is initiated.
The study …
-
Calliditas Therapeutics presents additional data analyses from phase 3 NeflgArd trial of Nefecon in primary IgAN at ISN World Congress of Nephrology 2024
19 Apr 2024 12:51 GMT
… year phase 3 NeflgArd trial evaluating Nefecon (Tarpeyo … without the study drug.
The primary efficacy … rare, progressive, chronic autoimmune disease that attacks the kidneys … on identifying, developing, and commercializing novel treatments in orphan …
-
Cell Therapy Treatment Effectively Treats Immune-Compromised Children
19 Apr 2024 08:58 GMT
… ) can effectively treat immunocompromised pediatric patients … Treatment Consortium (PIDTC) to create the first multi-center, pediatric-consortium trial … way for commercial development.”
The Good … including genetic and autoimmune diseases. “Future studies …
-
Could Some Auto-Immune Diseases Become a Thing of the Past?
18 Apr 2024 14:43 GMT
… auto-immune disease. She describes the decade-long journey to get treatment for an autoimmune disorder … more research in autoimmune diseases. Because unlike most autoimmune disorders, Long COVID … future generations is the development of an EBV vaccine. …
-
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
19 Apr 2024 05:00 GMT
… on the treatment of cancer and autoimmune diseases. Nykode’s … in autoimmune disorders, organ transplant rejections, anti-drug antibody … standards in clinical trials development, execution, analysis, … work directly with pharmaceutical organizations and operate …
-
Artiva doses first subject in Phase I lupus nephritis treatment trial
18 Apr 2024 16:55 GMT
… therapy candidate, AlloNK is being developed to boost the activity of … a US clinical trial for the treatment of an autoimmune disease.
“We are encouraged … B-cell subpopulations across different autoimmune diseases.”
Editorial content is independently produced …
-
Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
18 Apr 2024 15:39 GMT
… inhibitor, is used to treat a number of autoimmune … -mediated diseases by developing new treatments where significant medical … efficacy of continuing the drug compared with withdrawing … Common symptoms of the autoimmune disease include changes in vision …
-
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
18 Apr 2024 14:19 GMT
… Therapeutics (Formerly known as Pharmalink) (Nasdaq: CALT) (Nasdaq … medication: HR 0.44 (95% CI 0.27, 0.71). The treatment … rare, progressive, chronic autoimmune disease that attacks the kidneys and … disease. IgAN most often develops between late teens and …
-
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
18 Apr 2024 14:53 GMT
… 3rd Annual ALS Drug Development Summit and to … 47;/www.als-drug-development.com/
About … stage biotechnology company developing proprietary treatments focused on the … neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction …
-
Drug Infusion Systems Global Market Report 2024: Demand for Personalized Medicine and Adaptive Dosing Spurs Growth - Long-term Forecast to 2028 and 2033 - ResearchAndMarkets.com
18 Apr 2024 14:46 GMT
… autoimmune disorders often necessitate long-term or continuous infusion therapy. Drug … means of administering medication to patients with … actively engaged in developing innovative products … towards developing innovative products, such as medication delivery …